Moreno Evelyn V Takes Position in Eli Lilly And Co (NYSE:LLY)

Moreno Evelyn V purchased a new stake in shares of Eli Lilly And Co (NYSE:LLY) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 2,250 shares of the company’s stock, valued at approximately $249,000.

Other institutional investors have also added to or reduced their stakes in the company. WP Advisors LLC bought a new position in Eli Lilly And Co in the 1st quarter worth $38,000. Meridian Wealth Management LLC bought a new position in Eli Lilly And Co in the 1st quarter worth $38,000. Ellis Investment Partners LLC bought a new position in Eli Lilly And Co in the 1st quarter worth $39,000. Manchester Financial Inc. bought a new position in Eli Lilly And Co in the 2nd quarter worth $40,000. Finally, Litman Gregory Asset Management LLC bought a new position in Eli Lilly And Co in the 2nd quarter worth $47,000. Institutional investors and hedge funds own 79.48% of the company’s stock.

Several brokerages recently commented on LLY. TheStreet downgraded shares of Eli Lilly And Co from a “b+” rating to a “c+” rating in a report on Thursday, May 9th. Goldman Sachs Group started coverage on shares of Eli Lilly And Co in a report on Tuesday, May 28th. They issued a “buy” rating and a $135.00 target price on the stock. Edward Jones upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 price objective on the stock in a report on Tuesday, April 23rd. BMO Capital Markets boosted their price objective on shares of Eli Lilly And Co from $130.00 to $133.00 and gave the stock an “outperform” rating in a report on Wednesday, May 1st. Finally, ValuEngine downgraded shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Friday, June 28th. Nine research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $123.49.

In other news, CFO Joshua L. Smiley purchased 426 shares of Eli Lilly And Co stock in a transaction on Wednesday, June 5th. The shares were purchased at an average cost of $118.03 per share, for a total transaction of $50,280.78. Following the completion of the transaction, the chief financial officer now directly owns 30,410 shares in the company, valued at $3,589,292.30. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Michael J. Harrington sold 16,000 shares of the business’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $116.72, for a total transaction of $1,867,520.00. Following the completion of the transaction, the vice president now owns 110,300 shares in the company, valued at $12,874,216. The disclosure for this sale can be found here. 0.11% of the stock is owned by insiders.

Shares of NYSE:LLY traded down $0.08 on Thursday, hitting $110.21. 111,336 shares of the company were exchanged, compared to its average volume of 3,974,435. The firm’s 50 day moving average price is $110.66. Eli Lilly And Co has a one year low of $102.08 and a one year high of $132.13. The company has a debt-to-equity ratio of 4.98, a current ratio of 1.13 and a quick ratio of 0.87. The stock has a market capitalization of $109.60 billion, a price-to-earnings ratio of 19.90, a price-to-earnings-growth ratio of 2.01 and a beta of 0.19.

Eli Lilly And Co (NYSE:LLY) last issued its earnings results on Tuesday, July 30th. The company reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.45 by $0.05. Eli Lilly And Co had a net margin of 33.76% and a return on equity of 70.86%. The business had revenue of $5.64 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period in the previous year, the business earned $1.48 EPS. The firm’s revenue was up .9% on a year-over-year basis. As a group, equities analysts expect that Eli Lilly And Co will post 5.72 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be given a $0.645 dividend. The ex-dividend date is Wednesday, August 14th. This represents a $2.58 dividend on an annualized basis and a yield of 2.34%. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 46.49%.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: Support Level

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.